Management of primary sclerosing cholangitis
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Guidelines for clinical practice are intended to indicate preferred approaches to medical problems as established by scientifically valid research. Double blind, placebo-controlled studies are preferable, but reports and expert review articles are also utilized in a thorough review of the literature conducted through the National Library of Medicine's MEDLINE. When only data that will not withstand objective scrutiny are available, a recommendation is identified as a consensus of experts. Guidelines are applicable to all physicians who address the subject, without regard to specialty training or interests, and are intended to indicate the preferable but not necessarily the only acceptable approach to a specific problem. Guidelines are intended to be flexible and must be distinguished from standards of care that are inflexible and rarely violated. Given the wide range of specifics in any health care problem, the physician must always choose the course best suited to the individual patient and the variables in existence at the moment of decision. Guidelines are developed under the auspices of the American College of Gastroenterology and its Practice Parameters Committee and approved by the Board of Trustees. Each has been intensely reviewed and revised by the Committee, other experts in the field, physicians who will use them, and specialists in the science of decision of analysis. The recommendations of each guideline are therefore considered valid at the time of their production based on the data available. New developments in medical research and practice pertinent to each guideline will be reviewed at an established time and indicated at publication to assure continued validity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ursodiol for Primary Sclerosing Cholangitis
Lindor, K. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703063361003 · Cited by 598
Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497 · cited 1×
“Methyltestosterone (30), ursodiol (31), S-adenosylmethionine (32), ondansetron (33), prednisone, and ultraviolet light (34) have been used to control pruritus in individual patients but are tried only if all else fails.”
MethodNatural history and prognostic variables in primary sclerosing cholangitis
Farrant, J. M., Hayllar, K. M., Wilkinson, M. L., Karani, J., Portmann, B. C., Westaby, D., & Williams, R. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90673-9 · Cited by 468
Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial
Beuers, U., Spengler, U., Kruis, W., Aydemir, Ü., Wiebecke, B., Heldwein, W., Weinzierl, M., Pape, G. R., Sauerbruch, T., & Paumgartner, G. (1992) · Hepatology · doi:10.1002/hep.1840160315 · Cited by 448
Bergasa, N. V., Alling, D. W., Talbot, T. L., Swain, M. G., Yurdaydin, C., Turner, M. L., Schmitt, J. M., Walker, E. C., & Jones, E. A. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-3-199508010-00001 · Cited by 365
Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study
Wolfhagen, F., Sternieri, E., Hop, W., Vitale, G., Bertolotti, M., & Van Buuren, H. (1997) · Gastroenterology · doi:10.1053/gast.1997.v113.pm9322521 · Cited by 343
Effects of long-term rifampicin administration in primary biliary cirrhosis
Bachs, L., Parés, A., Elena, M., Piera, C., & Rodés, J. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90335-v · Cited by 235
Ursodeoxycholic acid for primary sclerosing cholangitis
Chazouillères, O., Poupon, R., Capron, J.-P., Metman, E.-H., Dhumeaux, D., Amouretti, M., Couzigou, P., Labayle, D., & Trinchet, J.-C. (1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90281-u · Cited by 165
Phenobarbital Effects in Cholestatic Liver Disease
BLOOMER, J. R., & BOYER, J. L. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-82-3-310 · Cited by 120
Guañabens, N., Parés, A., Ros, I., Alvarez, L., Pons, F., Caballería, L., Monegal, A., de Osaba, J. M. M., Roca, M., Peris, P., et al. (2003) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07639.x · Cited by 119
Cited by
AASLD practice guidelines: Evaluation of the patient for liver transplantation†
Murray, K. F., & Carithers, R. L. (2005) · Hepatology · doi:10.1002/hep.20704 · Cited by 939
Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and Management
Eaton, J. E., Talwalkar, J. A., Lazaridis, K. N., Gores, G. J., & Lindor, K. D. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.06.052 · Cited by 436
Patients With Primary Biliary Cirrhosis React Against A Ubiquitous Xenobiotic–Metabolizing Bacterium
Selmi, C., Balkwill, D. L., Invernizzi, P., Ansari, A. A., Coppel, R. L., Podda, M., Leung, P. S., Kenny, T. P., Van De Water, J., Nantz, M. H., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50446 · Cited by 312
Lakatos, L. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i10.2300 · Cited by 308
Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease
Takeda, K., Kojima, Y., Ikejima, K., Harada, K., Yamashina, S., Okumura, K., Aoyama, T., Frese, S., Ikeda, H., Haynes, N. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802702105 · Cited by 148
Metadata
- Authors
- Lee, Y.
- Venue
- The American Journal of Gastroenterology
- Published
- 2002-03
- Volume
- 97
- Issue
- 3
- Pages
- 528-534
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2134129999
- Cited by
- 63
- References
- 10
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of primary sclerosing cholangitis. https://app.cochat.ai/papers/10.1016/s0002-9270(01)04147-8
- The paper
- Lee, Y. (2002). Management of primary sclerosing cholangitis. The American Journal of Gastroenterology. https://doi.org/10.1016/s0002-9270(01)04147-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.